Good news for small molecule SARS-CoV-2 virus inhibitors: Pfizer demonstrates clinical efficacy!

Great news for researchers like us that are working on drug candidates to treat SARS-CoV-2 infections. Pfizer could demonstrate that its oral Covid drug PF-07321332 in combination with HIV drug Ritonavir cuts the risk of hospitalization or death by 89%.

Pfizers PF-07321332 is a small molecule compound targeting the viral cystein protease Mpro using a reversible covalent inhibitor approach. Together with Anixa we have used a similar approach to discover small molecule inhibitors of Mpro.

Leave a Reply

Your email address will not be published.

Consent Management Platform by Real Cookie Banner